JP6525203B2 - Ｃｆｔｒ活性を増大させるための方法 - Google Patents

Ｃｆｔｒ活性を増大させるための方法 Download PDF

Info

Publication number
JP6525203B2
JP6525203B2 JP2015504599A JP2015504599A JP6525203B2 JP 6525203 B2 JP6525203 B2 JP 6525203B2 JP 2015504599 A JP2015504599 A JP 2015504599A JP 2015504599 A JP2015504599 A JP 2015504599A JP 6525203 B2 JP6525203 B2 JP 6525203B2
Authority
JP
Japan
Prior art keywords
cftr
subject
depth
compound
mucociliary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015504599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521157A (ja
JP2015521157A5 (enExample
Inventor
エム． ロウ，スティーヴン
エム． ロウ，スティーヴン
ドランスフィールド，マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of JP2015521157A publication Critical patent/JP2015521157A/ja
Publication of JP2015521157A5 publication Critical patent/JP2015521157A5/ja
Application granted granted Critical
Publication of JP6525203B2 publication Critical patent/JP6525203B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2015504599A 2012-04-06 2013-03-15 Ｃｆｔｒ活性を増大させるための方法 Expired - Fee Related JP6525203B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621043P 2012-04-06 2012-04-06
US61/621,043 2012-04-06
PCT/US2013/032268 WO2013151758A2 (en) 2012-04-06 2013-03-15 Methods for increasing cftr activity

Publications (3)

Publication Number Publication Date
JP2015521157A JP2015521157A (ja) 2015-07-27
JP2015521157A5 JP2015521157A5 (enExample) 2016-05-12
JP6525203B2 true JP6525203B2 (ja) 2019-06-05

Family

ID=49301152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015504599A Expired - Fee Related JP6525203B2 (ja) 2012-04-06 2013-03-15 Ｃｆｔｒ活性を増大させるための方法

Country Status (8)

Country Link
US (2) US20150065539A1 (enExample)
EP (1) EP2833885A4 (enExample)
JP (1) JP6525203B2 (enExample)
CN (1) CN104619321A (enExample)
AU (2) AU2013243857A1 (enExample)
CA (1) CA2869257A1 (enExample)
HK (1) HK1206995A1 (enExample)
WO (1) WO2013151758A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690023A5 (de) * 1996-02-02 2000-03-31 Medichemie Ag Mittel zur Behandlung krankhafter Zellveränderungen der Nasenschleimhaut.
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
KR20110042356A (ko) * 2008-08-13 2011-04-26 버텍스 파마슈티칼스 인코포레이티드 제약 조성물 및 그의 투여
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
BR112012005517A2 (pt) * 2009-09-12 2016-04-19 Reckitt Benckiser Llc uso de guaifenesina para inibição da secreção de mucina
US20130005822A1 (en) * 2010-03-15 2013-01-03 Rubin Bruce K Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
US8471029B2 (en) * 2010-03-19 2013-06-25 Vertex Pharmaceutical Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
DK3235812T3 (da) * 2011-05-18 2019-11-25 Vertex Pharmaceuticals Europe Ltd Deutererede derivater af ivacaftor

Also Published As

Publication number Publication date
HK1206995A1 (en) 2016-01-22
JP2015521157A (ja) 2015-07-27
EP2833885A2 (en) 2015-02-11
US20150065539A1 (en) 2015-03-05
US20170266177A1 (en) 2017-09-21
AU2013243857A1 (en) 2014-10-16
CA2869257A1 (en) 2013-10-10
US10300052B2 (en) 2019-05-28
WO2013151758A2 (en) 2013-10-10
AU2018200192A1 (en) 2018-02-01
AU2018200192B9 (en) 2019-07-25
AU2018200192B2 (en) 2019-06-06
EP2833885A4 (en) 2015-12-16
CN104619321A (zh) 2015-05-13

Similar Documents

Publication Publication Date Title
Brand et al. Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis
Chambers et al. Liquid movement across the surface epithelium of large airways
US7524820B1 (en) Compounds of therapeutic value in the treatment of multiple sclerosis and other diseases wherein foamy cells are involved in the disease etiology
McGowan et al. Platelet-derived growth factor-A and sonic hedgehog signaling direct lung fibroblast precursors during alveolar septal formation
JP2022078013A (ja) エラスターゼ阻害活性を有するベータヘアピンペプチド模倣体及びそのエアロゾル剤形
CN101583377A (zh) 纤维化的治疗
Maguire et al. Sphingosine-1-phosphate induces airway smooth muscle hyperresponsiveness and proliferation
US20080020031A1 (en) Methods and compositions for altering mucus secretion
AU2018200192B2 (en) Methods for increasing CFTR activity
EP1538162B1 (en) Compositions for altering mucus secretion
US20140309300A1 (en) Bicyclic Labdane Diterpenes for Use in the Treatment of TRPC6 Associated Diseases
Jiao et al. Regulation of ciliary beat frequency by the nitric oxide signaling pathway in mouse nasal and tracheal epithelial cells
US9844556B2 (en) Preventive/therapeutic method and preventive/therapeutic agent for complications after cataract surgery
Do et al. Decreased ciliary beat responsiveness to acetylcholine in the nasal polyp epithelium
US20220347167A1 (en) A new treatment for meibomian gland dysfunction
US7265088B1 (en) Method and compositions for altering mucus secretion
JP5283962B2 (ja) 医薬組成物
WO2022007743A1 (zh) 粘膜给药剂型和其应用
Fluor 4. Functional Assays
Nguyen et al. Mucociliary transport velocity is decreased in nasal polyp mucosae despite vigorous ciliary beating
Singh et al. MAPK and Hsp27 Activation Are Associated With RSV Induction of Human Bronchial Epithelial Monolayer Disruption
Popov Development of inhaled CaSR NAMs for the treatment of pulmonary disorders
Acosta Advanced Design and Development of Novel Microparticulate/Nanoparticulate Dry Powder Inhalers for Targeted Treatment of Pulmonary Hypertension
Kaur Live Imaging to Investigate Organelle Form and Function in the Retinal Pigment Epithelium
Kantar et al. Flunisolide attenuates nitric oxide-induced DNA damage in rat trachea epithelial cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180627

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190118

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190424

R150 Certificate of patent or registration of utility model

Ref document number: 6525203

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees